Replies to post #19755 on Predictive Technology Group Inc (PRED)

[Marty Byrd]

351 path and 361 paths are quite different in time frames and costs. If it is 351 path, best to exit and concentrate on core business and not stem cells.

[Brian903]

That is the only stand out information- No prediction on revenue, no talk of nasdaq, no talk of China - this is what we have and the expectation the new tests will perform well.

I am ok for the minute-

Just wish we would have addressed the problems as they came about...specifically delist

[Marty Byrd]

Hopefully it will cut a lot of time and cost from the process